Skip to main content

Table 1 Baseline characteristics of included randomized controlled trials

From: Glucagon-like peptide-1 receptor agonists and heart failure in type 2 diabetes: systematic review and meta-analysis of randomized and observational studies

Study International study Number of countries involved Number of study sites Study phase Total number of patients randomized Length of follow up (weeks) Male (n,%) Mean age (years) Mean BMI (kg/m2) Mean HbA1c (%) Mean FPG (mmol/L) Mean diabetes duration (years)
Trials reporting heart failure
 Inagaki 2012 [38, 39] No 1 NR III 427 26 290 (67.9) 56.8 26.1 8.5 NR 9.0
 NCT00294723 2010 [40, 41] Yes 2 138 III 746 104 371 (49.7) 53.0 33.1 8.3 9.4 5.4
 NCT00318461 2010 [4244] Yes 21 170 III 1091 104 635 (58.2) 56.7 31.0 8.4 10.0 7.6
 NCT00360334 2009 [45] No 1 35 III 235 26 160 (68.4) 56.6 NR NR NR 6.0
 NCT00614120 2010 [46] Yes 3 51 III 929 16 514 (55.3) 53.3 25.6 NR NR 7.5
 NCT00701935 2013 [47] Yes 2 17 II 80 26 42 (52.5) 58.1 NR NR NR NR
 NCT00838903 2014 [48, 49] Yes 10 289 III 1049 164 482 (47.6) 54.5 32.6 8.1 9.2 6.0
 NCT00838916 2014 [50, 51] Yes 4 222 III 779 164 418 (56.1) 55.5 33.1 8.3 9.5 8.8
 NCT00839527 2014 [52] Yes 9 358 III 685 164 353 (53.2) 55.2 NR NR NR NR
 NCT00849017 2014 [53] Yes 3 262 III 309 164 166 (55.1) 52.9 NR NR NR NR
 NCT00849056 2014 [54] Yes 6 331 III 310 156 180 (59.8) 55.0 NR NR NR NR
 NCT00855439 2015 [55] No 1 1 NR 46 82 26 (56.5) 53.0 NR NR NR NR
 NCT00960661 2013 [56, 57] Yes 17 108 III 637 30 261 (51.2) 59.5 32.5 8.2 7.1 11.5a
 NCT01064687 2015 [58] Yes 3 89 III 978 26 570 (58.4) 55.7 33.2 8.1 9.0 8.8
 NCT01075282 2015 [59] Yes 20 78 III 810 78 353 (51.3) 56.7 31.6 8.1 9.1 9.1
 NCT01126580 2015 [60, 61] Yes 19 91 III 807 56 353 (43.7) 55.6 33.3 7.6 9.0 2.6
 NCT01191268 2014 [62] Yes 16 101 III 884 52 473 (53.5) 59.4 32.5 8.5 NR 12.7
 NCT01512108 2014 [63] No 1 36 III 363 52 262 (72.8) 59.5 NR 8.1 8.8 NR
 NCT01620489 2014 [64] Yes 6 50 III 277 26 140 (50.5) 67.2 NR NR NR NR
 Pratley 2013 [65] Yes 17 130 III 760 24 362 (48.9) 56.4 32.7 8.3 10.0 8.8
Trials reporting hospitalization for heart failure
 Bentley-Lewis 2015 (ELIXA) [15, 16] Yes 49 NR III 6068 108b 4207 (69.3) 60.3 30.2 7.7 8.2 9.3
  1. BMI body mass index, FPG fasting plasma glucose, NR not reported
  2. amedian diabetes duration (years); bmedian follow up time (weeks)